![Editors in Conversation artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts113/v4/b8/68/dd/b868dd9f-5a51-91c9-fb51-f8d1567e8465/mza_5151066038574592298.jpg/100x100bb.jpg)
Treatment of Acinetobacter spp. Infections (AAC ed.)
Editors in Conversation
English - December 11, 2021 00:29 - 43 minutes - 30.2 MB - ★★★★ - 10 ratingsLife Sciences Science Health & Fitness Medicine asm for fox interviews jeff magazine microbe microbiology news science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: SARS-CoV-2 Sequencing for Clinical Care and Infection Control
Next Episode: Best Clinical Microbiology Papers of 2021 (JCM ed.)
Infections caused by carbapenem-resistant Acinetobacter spp. are considered an urgent public health problem. Antibiotic options are scarce but new drugs may be available in the near future. We discuss this important topic with experts in the field.
Topics discussed: Acinetobacter as an opportunistic pathogen Therapeutic approaches for Acinetobacter infections The future approach for this MDR organisms. Guests: Dr. Yohei Doi, Professor and Director, Center for Innovative Antimicrobial Therapy, University of Pittsburgh Medical Center, Pittsburgh, PA Dr. Joseph Patrick Hornak. Fellow, Infectious Diseases, University of Texas Medical Branch, Galveston, TX